![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Up to 91% SVR rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a (40KD)/ribavirin (P/R) in HCV genotype (G)1b-infected prior partial/null responders
|
|
|
Reported by Jules Levin
APASL 2013 Singapore June 6-10
G.R. Foster, J.J. Feld, I.M. Jacobson, D.M. Jensen, S. Pol, E.J. Gane, R. Rouzier, A. Wiercinska-Drapalo, P.N. Morcos, B.J. Brennan, S. Shadad, R. Kulkarni, M.T. Navarro, P. Smith, E.S. Yetzer, N.S. Shulman, on behalf of the MATTERHORN and MAD NP22660 study groups
![APASL1.gif](../images/061913/061913-10/APASL1.gif)
![APASL2.gif](../images/061913/061913-10/APASL2.gif)
![APASL3.gif](../images/061913/061913-10/APASL3.gif)
![APASL4.gif](../images/061913/061913-10/APASL4.gif)
![APASL5.gif](../images/061913/061913-10/APASL5.gif)
![APASL6.gif](../images/061913/061913-10/APASL6.gif)
![APASL7.gif](../images/061913/061913-10/APASL7.gif)
![APASL8.gif](../images/061913/061913-10/APASL8.gif)
![APASL9.gif](../images/061913/061913-10/APASL9.gif)
![APASL10.gif](../images/061913/061913-10/APASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|